STOCK TITAN
  1. Home
  2. Sec-filings
  3. BLTE
  4. [Form 3] BELITE BIO, INC Initial Statement of Beneficial Ownership

Belite Bio (NASDAQ: BLTE) CMO details option grants and indirect holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

BELITE BIO, INC Chief Medical Officer Hendrik Peter Scholl filed an initial ownership report showing indirect equity positions held through Bioptima Ltd. These include stock options over 100,000, 75,000 and 40,000 ordinary shares with exercise prices of 48.6800, 54.8800 and 158.3600, expiring between 2034 and 2036, plus 35,000 ordinary shares. Footnotes describe time-based vesting, with portions of these options vesting around September 1, 2025 and January 9 in 2027, 2028 and 2029, subject to continued service.

Positive

  • None.

Negative

  • None.
Insider Scholl Hendrik Peter
Role Chief Medical Officer
Type Security Shares Price Value
holding Stock Option (right to buy) -- -- --
holding Stock Option (right to buy) -- -- --
holding Stock Option (right to buy) -- -- --
holding Ordinary Share -- -- --
Holdings After Transaction: Stock Option (right to buy) — 100,000 shares (Indirect, By Bioptima Ltd.); Ordinary Share — 35,000 shares (Indirect, By Bioptima Ltd.)
Footnotes (1)
  1. The option shall vest (i) as to 50,000 ordinary shares on the first anniversary of September 1, 2024, and (ii) as to 50,000 ordinary shares in 24 equal and continuous monthly installments for each full month following the first anniversary of September 1, 2024, subject to continued service to the Issuer on each such date. The option shall vest (i) as to 12,500 ordinary shares on September 1, 2025, and (ii) as to 62,500 ordinary shares in 30 equal and continuous monthly installments for each full month following September 1, 2025, subject to continued service to the Issuer on each such date. The option shall vest (i) as to 13,333 ordinary shares on January 9, 2027, (ii) as to 13,333 ordinary shares on January 9, 2028, and (iii) as to 13,334 ordinary shares on January 9, 2029.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Scholl Hendrik Peter
(Last)(First)(Middle)
GOTTHARDSTRASSE 26
(Street)
ZUGSWITZERLAND6300
(City)(State)(Zip)
SWITZERLAND
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Share35,000IBy Bioptima Ltd.
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) (1)08/31/2034Ordinary Shares100,000$48.68IBy Bioptima Ltd.
Stock Option (right to buy) (2)02/11/2035Ordinary Shares75,000$54.88IBy Bioptima Ltd.
Stock Option (right to buy) (3)01/08/2036Ordinary Shares40,000$158.36IBy Bioptima Ltd.
Explanation of Responses:
1. The option shall vest (i) as to 50,000 ordinary shares on the first anniversary of September 1, 2024, and (ii) as to 50,000 ordinary shares in 24 equal and continuous monthly installments for each full month following the first anniversary of September 1, 2024, subject to continued service to the Issuer on each such date.
2. The option shall vest (i) as to 12,500 ordinary shares on September 1, 2025, and (ii) as to 62,500 ordinary shares in 30 equal and continuous monthly installments for each full month following September 1, 2025, subject to continued service to the Issuer on each such date.
3. The option shall vest (i) as to 13,333 ordinary shares on January 9, 2027, (ii) as to 13,333 ordinary shares on January 9, 2028, and (iii) as to 13,334 ordinary shares on January 9, 2029.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Hendrik Peter Scholl03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does Belite Bio (BLTE) Chief Medical Officer report on this Form 3?

The Chief Medical Officer reports initial beneficial ownership of Belite Bio securities. Indirectly through Bioptima Ltd., he holds three stock option grants over 215,000 ordinary shares plus 35,000 ordinary shares, establishing his starting equity position as an insider.

How many Belite Bio (BLTE) options does the CMO hold through Bioptima Ltd.?

The CMO indirectly holds stock options over 215,000 ordinary shares of Belite Bio. These consist of separate grants for 100,000, 75,000 and 40,000 underlying ordinary shares, each with its own exercise price and expiration date extending from 2034 to 2036.

What are the exercise prices and expirations of the Belite Bio (BLTE) options?

The reported options have exercise prices of 48.6800, 54.8800 and 158.3600. Their expiration dates are August 31, 2034, February 11, 2035 and January 8, 2036, respectively, providing long-dated potential equity exposure for the Chief Medical Officer.

How many Belite Bio (BLTE) ordinary shares does the CMO indirectly own?

In addition to options, the CMO indirectly holds 35,000 Belite Bio ordinary shares. These shares are reported as held by Bioptima Ltd., reflecting indirect ownership rather than shares registered directly in the executive’s own name.

How do the Belite Bio (BLTE) option vesting schedules work for the CMO?

The footnotes show time-based vesting tied to continued service. Portions vest on the first anniversary of September 1, 2024, then in equal monthly installments, with additional blocks vesting on September 1, 2025 and on January 9 in 2027, 2028 and 2029.

Are the Belite Bio (BLTE) holdings on this Form 3 direct or indirect?

All reported positions are indirect, held through Bioptima Ltd. The filing lists stock options and ordinary shares with ownership type marked as indirect, meaning the securities are registered to that entity rather than directly to the Chief Medical Officer.